Abstract:Novel inhibitors are urgently needed for use as targeted therapies to improve the overall survival (OS) of patients with ovarian cancer. Here, we show that cell division cycle 25B (CDC25B) is over-expressed in ovarian tumors and associated with poor patient prognosis. All previously reported CDC25B inhibitors have been identified by their ability to reversibly inhibit the catalytic dephosphorylation activity of CDC25B in vitro; however, none of these compounds have entered clinical trials for ovarian cancer therapy. In this study, we synthesized a novel small molecule compound, WG-391D, that potently down-regulates CDC25B expression without affecting its catalytic dephosphorylation activity. The inhibition of CDC25B by WG-391D is irreversible, and WG-391D should therefore exhibit potent antitumor activity against ovarian cancer. WG-391D induces cell cycle progression arrest at the G2/M phase. Half maximal inhibitory concentration (IC50) values of WG-391D for inhibition of the proliferation and migration of eight representative ovarian cancer cell lines (SKOV3, ES2, OVCAR8, OVTOKO, A2780, IGROV1, HO8910PM, and MCAS) and five primary ovarian tumor cell lines (GFY004, GFY005, CZ001, CZ006, and CZ008) were lower than 10 and 1 μM, respectively. WG-391D inhibited tumor growth in nude mice inoculated with SKOV3 cells or a patient-derived xenograft (PDX). The underlying mechanisms were associated with the down-regulation of CDC25B and subsequent inactivation of cell division cycle 2 (CDC2) and the serine/threonine kinase, AKT. In conclusion, this study demonstrates that WG-391D exhibits strong antitumor activity against ovarian cancer and indicates that the down-regulation of CDC25B by inhibitors could provide a rationale for ovarian cancer therapy.

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Immunomodulatory Effects of CDK4/6 Inhibitors

Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.

Knockdown of Creatine Kinase B Inhibits Ovarian Cancer Progression by Decreasing Glycolysis

CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner

Inhibition of CDC25B with WG-391D Impedes the Tumorigenesis of Ovarian Cancer

Effects of a Selective Cyclooxygenase-1 Inhibitor in SKOV-3 Ovarian Carcinoma Xenograft-Bearing Mice.

MiR-506 Suppresses Proliferation and Induces Senescence by Directly Targeting the CDK4/6-FOXM1 Axis in Ovarian Cancer.

Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1

Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

Role of Glycogen Synthase Kinase-3&Amp;beta; Inhibitor AZD1080 in Ovarian Cancer

Dicumarol Inhibits PDK1 and Targets Multiple Malignant Behaviors of Ovarian Cancer Cells

Cholesterol Biosynthesis Inhibitor RO 48‑8071 Inhibits Pancreatic Ductal Adenocarcinoma Cell Viability by Deactivating the JNK and ERK/MAPK Signaling Pathway

Cyclin-dependent kinase 7 gene silencing or knockout represses proliferation of ovarian cancer cells and the mechanism research

Cytidine Monophosphate Kinase is Inhibited by the TGF-β Signalling Pathway Through the Upregulation of Mir-130B-3p in Human Epithelial Ovarian Cancer.

Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.

Data on the Association of Cmpk1 with Clinicopathological Features and Biological Effect in Human Epithelial Ovarian Cancer

The Oncogenic And Prognostic Role Of Pdk1 In The Progression And Metastasis Of Ovarian Cancer

Pharmacological Inhibition Of P38 Mapk By Sb203580 Increases Resistance To Carboplatin In A2780cp Cells And Promotes Growth In Primary Ovarian Cancer Cells